Personalis, Inc. Q3 2025 Earnings Recap

PSNL Q3 2025 November 5, 2025

Personalis achieved significant growth in Q3 2025 with a 364% year-over-year increase in clinical tests, reflecting strong demand for its ultrasensitive NeXT Personal test, while adjusting revenue guidance due to biopharma project timing variability.

Earnings Per Share Beat

$-0.24 vs $-0.28 est.

+14.3% surprise

Revenue Miss

14495000 vs 17040000 est.

-14.9% surprise

Market Reaction

1-Day -12.26%

5-Day -1.15%

30-Day +22.91%

Key Takeaways

Revenue of $14.5 million surpassed expectations, driven by 4,388 clinical tests delivered in the quarter.
Growth in clinical adoption highlighted by over 700 physicians now ordering NeXT Personal.
Submitted additional coverage application for lung cancer, with three dossiers currently under review by MolDX.
Despite uneven biopharma spending, underlying demand for MRD technology remains strong, supporting long-term growth strategy.
Full-year revenue guidance adjusted to $68 million - $73 million, reflecting project timing volatility rather than demand changes.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit PSNL on AllInvestView.